VIVUS, Inc., has announced that the FDA has accepted its new drug application for the company’s Qnexa, a phentermine/topiramate combination. The low-dose,…
Qnexa, a drug in development by VIVUS, is one of several promising drugs for the treatment of obesity that received adverse FDA…
Qnexa, a drug in development by VIVUS, is one of several promising drugs for the treatment of obesity that received adverse FDA…